CJC-1295

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — a peptide your hypothalamus naturally produces to signal your pituitary gland to release growth hormone. CJC-1295 mimics that signal. The key distinction from direct GH injection: you're stimulating your own pituitary to produce GH, which means your body's natural feedback loops remain largely intact, pulsatile GH release is preserved, and you're not suppressing endogenous production the way exogenous GH therapy does.

It comes in two fundamentally different versions. CJC-1295 with DAC (Drug Affinity Complex) has a chemical modification that lets it bind to albumin in your blood — protecting it from enzymatic degradation and extending its half-life to 5.8–8.1 days. One or two injections per week creates sustained GH and IGF-1 elevation. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) is cleared within 30 minutes to 2 hours, producing brief, sharp GH pulses. Daily injections, but a profile that more closely mimics your body's natural pulsatile GH rhythm.

The human data comes primarily from Phase I/II trials conducted in 2005–2006, which showed dose-dependent, sustained GH and IGF-1 elevation with good short-term tolerability. Development was later paused after an adverse event in a Phase II trial. No Phase III trials were completed. The compound has real human evidence for its pharmacological mechanism — but the safety and efficacy evidence for the specific goals biohackers care about (body recomposition, anti-aging) is extrapolated from mechanism and preclinical data rather than directly established in trials.

The DAC vs. no-DAC choice is genuinely philosophical. With DAC: convenience, sustained anabolism, theoretical receptor desensitization risk. Without DAC: daily injections, better mimicry of natural GH pulsatility, lower desensitization concern, and the foundation for the CJC-1295 + ipamorelin stack — the most popular GH-optimization protocol in the biohacker community.

How it works

How GHRH Signaling Works

Your hypothalamus produces GHRH in pulses, signaling pituitary somatotroph cells to secrete GH. GH then travels to the liver and stimulates IGF-1 production — the primary mediator of GH's anabolic effects. CJC-1295 binds to GHRH receptors on those same pituitary cells, activating the adenylyl cyclase → cAMP → PKA → GH gene transcription pathway. The result is GH secretion.

The DAC Modification — Why It Changes Everything

Natural GHRH is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) within minutes. The DAC modification — a chemical linker that enables binding to albumin — completely changes the pharmacokinetics. Albumin has a half-life of roughly 19 days; by binding to it, CJC-1295 DAC is protected from degradation and remains active for 5.8–8.1 days after a single injection.

Sustained vs. Pulsatile GH Release

CJC-1295 with DAC creates sustained GH elevation across the entire week. IGF-1 elevates correspondingly and remains above baseline for 9–11 days after a single dose; multiple weekly doses produce cumulative elevation lasting up to 28 days. Human trial data confirmed that even with continuous CJC-1295 stimulation, GH pulsatility is preserved — the peptide amplifies existing pulses rather than flattening them. The receptor desensitization concern is theoretically plausible but not proven in humans at typical biohacker doses.

IGF-1 and Downstream Effects

Both versions of CJC-1295 ultimately elevate IGF-1, which drives protein synthesis via mTOR (muscle growth), lipolysis via hormone-sensitive lipase (fat breakdown), collagen synthesis (skin, joint, tendon health), bone mineral density support, and improved glucose uptake in muscle. These downstream effects of GH/IGF-1 elevation are well-characterized — the mechanism exists. Whether CJC-1295 at typical doses produces meaningful clinical outcomes for these parameters in healthy adults is less established.

What the research shows

What the community reports

CJC-1295 has one of the longest community track records of any peptide in the biohacker GH-optimization space. The accumulated practical experience — particularly around the CJC-1295 + ipamorelin stack — is substantial and worth taking seriously as a real-world signal alongside the clinical data.

Biology is individual. Age matters particularly — someone in their 30s with naturally declining GH may respond more noticeably than someone in their mid-20s with still-robust GH secretion. Track your own response, not just the average forum report.

Common misconceptions